ClinicalTrials.gg
Not yet recruitingNCT07896967PV-INTERACTUpdated Oct 27, 2026

Impact of Inspiratory Effort and Patient-Ventilator Interaction During the Transition Phase

An observational study in Mechanically Ventilated Patients and Acute Respiratory Failure (ARF), sponsored by Pontificia Universidad Catolica de Chile. Not yet recruiting at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Pontificia Universidad Catolica de Chile · Observational

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn whether breathing effort and patient-ventilator asynchrony (PVA) during the transition phase are associated with clinical outcomes in mechanically ventilated adults.The main questions it aims to answer are:

  • Is the level and change in breathing effort associated with successful liberation from mechanical ventilation?
  • How often does PVA occur during the transition phase?
  • Are breathing effort and PVA associated with patient outcomes?

These questions will be assessed using physiological and clinical data collected during the transition phase of mechanical ventilation. Breathing effort will be measured twice daily using a non-invasive airway pressure measurement, while ventilator waveforms will be continuously monitored to detect PVA. Participants will be followed up at day 28 and day 90.

Read the detailed description

The transition phase of mechanical ventilation is a critical but understudied period in which spontaneous breathing gradually increases as ventilatory support is reduced. Both insufficient and excessive inspiratory effort, as well as patient-ventilator asynchrony (PVA), may contribute to lung and diaphragm injury, prolonged mechanical ventilation and worse clinical outcomes. However, the relationship between inspiratory effort, PVA and outcomes during this phase remains incompletely understood.

In this multicenter prospective observational study, the investigators will assess inspiratory effort using airway occlusion pressure (ΔPocc) and continuously monitor patient-ventilator interaction using ventilator waveform recordings. Adult patients entering the transition phase of invasive mechanical ventilation will be followed during this period and through day 90. ΔPocc will be measured twice daily, while PVA will be assessed continuously using breath-by-breath monitoring.

The primary outcome will be time to successful liberation from mechanical ventilation within 28 days. Secondary outcomes will include ventilator-free days at day 28, ICU and hospital length of stay, 28- and 90-day mortality, weaning failure or reintubation, tracheostomy, and the incidence and magnitude of patient-ventilator asynchrony.

02

Conditions studied

  • Mechanically Ventilated Patients
  • Acute Respiratory Failure (ARF)

Keywords

  • Patient-ventilator asynchrony
  • Transition phase
  • Mechanical ventilation
  • Respiratory effort
  • Work of Breathing
03

In context

Patient-Ventilator Asynchrony

24 studies on the registry are indexed under Patient-Ventilator Asynchrony; 11 are open to participants now.

This study's planned enrollment of 250 is above the median of 40 across 13 observational studies indexed under Patient-Ventilator Asynchrony.

Browse Patient-Ventilator Asynchrony studies →

Lead sponsor

Pontificia Universidad Catolica de Chile is the lead sponsor of 224 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients admitted to the ICU that receive invasive mechanical ventilation entering the transition phase

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (>=18 years) intubated and receiving invasive mechanical ventilation delivered through an endotracheal tube within the first 48 hours from initiation of ventilation.
  • No immediate plan for extubation within the next 48 hours, a determined by the treating clinical team.
  • Patients clinically stable entering the transition phase of mechanical ventilation *

For prospective enrollment and initiation of active monitoring, the transition phase will be identified clinically. A patient will be considered to be entering the transition phase when there is improvement or partial resolution of the acute phase and the treating team initiates at least one clinical action indicating an intention to allow greater spontaneous respiratory participation. These actions may include: reducing or discontinuing sedation, decreasing the set respiratory rate, changing to a ventilatory mode allowing greater patient participation, decision to assess spontaneous breathing or advance liberation from mechanical ventilation.

For the final analysis, the physiological onset of the transition phase will be determined retrospectively from the continuous ventilator waveform recordings. It will be defined as the first sustained 30-minute period during which at least 50% of ventilator-delivered breaths are triggered by the patient. This physiological criterion will be used to align individual trajectories and define the analytical onset of transition*

Exclusion criteria

Exclusion Criteria:

  • Pre-existing neurological or muscular conditions (e.g., subarachnoid hemorrhage, diaphragm paralysis)
  • History of recovered cardiocirculatory arrest
  • Extra-corporeal membrane oxygenation (ECMO)
  • Current pregnancy
  • Documented intellectual or psychiatric disability prior to hospitalization
  • A decision to withhold or withdraw life-sustaining treatment
  • Patients undergoing a second episode of mechanical ventilation during the same hospitalization
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult patients admitted to the ICU that receive invasive mechanical ventilation

    * Adult patients (\>=18 years) intubated and receiving invasive mechanical ventilation delivered through an endotracheal tube within the first 48 hours from initiation of ventilation. * No immediate plan for extubation within the next 48 hours, a determined by the treating clinical team. * Patients clinically stable entering the transition phase of mechanical ventilation

    Other: PVA classification software

Interventions

  • OtherPVA classification software

    Patients will receive standard care. Clinical and physiological data will be collected systematically for up to 7 days during the transition phase.Patient-ventilator asynchrony will be continuously monitored using a using dedicated offline software (DeepBreath platform via the BreathBox device). Inspiratory breathing effort will be quantified using ΔPocc, performed during the morning (08:00-10:00 h) and afternoon (18:00-20:00 h) assessment periods

06

What researchers measure

Primary outcomes

  1. Successful liberation from mechanical ventilation within 28 days of enrollment

    Defined as the time from entry into the transition phase (study enrollment) to the first episode of sustained extubation, lasting at least 7 days

    Time frame: 28 days

Secondary outcomes

  1. Ventilator free days (at day 28)

    Number of ventilator free days at day 28

    Time frame: 28 days

  2. ICU length of stay (28 days)

    Length of ICU stay, measured in days from enrollment

    Time frame: 28 days

  3. ICU length of stay (at day 90)

    ICU length of stay, measured in days from enrollment

    Time frame: 90 days

  4. Mortality at day 28

    Mortality at day 28

    Time frame: 28 days

  5. Mortality at day 90

    Mortality at day 90

    Time frame: 90 days

  6. Incidence of weaning failure or reintubation

    reintubation within 7 days after extubation.

    Time frame: 7 days

  7. Rate of complications

    including tracheostomy and resumption of sedatives

    Time frame: 28 days

  8. Physiological characterization

    based on different inspiratory effort levels (ΔPocc)

    Time frame: 7 days

  9. Incidence (AI) of patient-ventilator asynchrony

    Number of asynchronous respiratory cycles, expressed as a proportion of the total respiratory cycles recorded, overall and by PVA type.

    Time frame: 7 days

  10. Mechanical ventilation settings

    Main parameters obtained from the mechanical ventilator to describe the population such as Tidal volume (liters), PEEP(cmH2O), peak pressure (cmH2O), pressure support (cmH2O), inspiratory time (seconds), respiratory rate (n/min), FIO2 (%), plateau pressure(cmH2O), driving pressure(cmH2O), static compliance (ml/cmH20)

    Time frame: 7 days

  11. Gas exchange parameters

    e.g. PaO2 (mmhg), PaCO2 (mmhg) bicarbonate (mEq/L)

    Time frame: 7 days

  12. Relevant medication

    e.g. vasoactive agents, delirium related medication

    Time frame: 7 days

  13. Illness severity score (SOFA-score)

    SOFA-score. This score ranges from 0-24, with increasing scores reflecting more abnormal physiology and biochemistry or an increasing degree of intervention.

    Time frame: 7 days

  14. Use of sedatives (cumulative dose and type)

    Time frame: 7 days

  15. Reported delirium

    CAM-ICU

    Time frame: 7 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 27, 2026
StartEst.
Nov 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07896967
Collaborators
Hospital Clinico Universidad Catolica, Hospital Civil Fray Antonio Alcalde, University Hospital Padova, Clínica San Carlos de Apoquindo
Responsible party
Sponsor
First posted
Oct 27, 2026
Start date
Nov 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Felipe Damiani, PT, Msc, PhD
Contact
lfdamiani@gmail.com
+56966698823 ext. +56 9 6669 882
Eduardo Kattan, MD, PhD
Contact
e.kattan@gmail.com
+56994793024
Felipe Damiani, PT, Msc, PhD
principal investigator · Escuela de Ciencias de la Salud, Pontificia Universidad Católica de Chile Santiago, Chile
Eduardo Kattan, MD, PhD
study chair · Departamento de Medicina Intensiva, Pontificia Universidad Católica de Chile Santiago, Chile
Alejandro Bruhn, MD, PhD
study chair · Departamento de Medicina Intensiva, Pontificia Universidad Católica de Chile Santiago, Chile

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion